- SunPharm has determined the maximum tolerated dose in its Phase I trial of diethylnorspermine, a synthetic polyamine analog in development for cancer. Naturally-occurring polyamines are necessary for cell proliferation. This puts the firm on track to complete its Phase I program by second-quarter 1996, whereupon partner Warner-Lambert will assume responsibility for further development of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze